RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

NCT02128113 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

307

Enrollment

INDUSTRY

Sponsor class

Conditions

Corneal Endothelial Cell Loss
Ocular Pain
Ocular Inflammation
Cataract Surgery

Interventions

DRUG: Vehicle Ophthalmic Solution
DRUG: Omaveloxolone Ophthalmic Suspension 0.5%
DRUG: Omaveloxolone Ophthalmic Suspension 1%

Sponsor

Biogen

Collaborators

[object Object]